2 registrations that name bromelain as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 2 registrations
Status
Phase
1US sites across 1 state
1
2 to 4
5 to 19
20 or more
All 2 registrations
RecruitingNCT07115212
Bromelain for Post-surgery Facial Swelling
No phase
Mohamed Bazina
About 200 people
Started Sep 8, 2025
In plain words A study of bromelain in people 18 to 65, run by Mohamed Bazina. It plans to enroll about 200 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65. Conditions: Malocclusion.
undergoing orthognathic surgery
The exclusion criteria are on the listing.
What it tests, as registered
Bromelain
Registered summary
The goal of this clinical trial is to learn if Bromelain Supplement works to decrease the amount of swelling or the amount of time swelling is present following jaw surgery. It will also learn about the safety of Bromelain supplement. The main questions it aims to answer are: Does Bromelain decrease facial swelling following orthognathic, or jaw, surgery? Does Bromelain supplement decrease the amount of time that patients are swollen following orthognathic, or jaw, surgery? Participants will: Take Bromelain supplement once daily for 9 days total. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
Not yet recruitingNCT06786403
The Effects of Bromelain Supplement in Patients with Diabetic Foot Ulcers
Phase 3
Dr Azita Hekmatdoost
About 70 people
Starts Mar 2025 (estimated)
In plain words A Phase 3 study of bromelain in people 18 and older, run by Dr Azita Hekmatdoost. It plans to enroll about 70 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Diabetic Foot Ulcer (DFU).
Patients over 18 years old
Patients diagnosed with diabetic foot ulcers of category 0, 1 and 2 according to the Wagner criteria
Patients aware of the study process for monitoring after filling out the informed consent form
The exclusion criteria are on the listing.
What it tests, as registered
Bromelain; Placebo
Registered summary
This study will be conducted on people over 18 with diabetic foot ulcers.. The first group will receive the standard treatment along with bromelain supplement and the second group will receive the standard treatment and placebo. The informed consent form prepared in advance will also be provided to the patients so that they are fully familiar with the study process. Wound surface area, rate of pain, rate of inflammatory factors (ESR and CRP) will be assessed at baseline and every two weeks.